Clinical Trial Update: Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether dexlansoprazole 60 mg once daily or twice daily reduces recurrence of intestinal metaplasia after complete eradication of Barre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Barrett Esophagus

Drugs mentioned

• DEXLANSOPRAZOLE (DEXLANSOPRAZOLE)

Snippet

Sponsor: Takeda | Conditions: Barrett's Esophagus | Phase 2 | Status: TERMINATED | Results posted: 2017-05-11